바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.57 No.6
Citation Share

Effects of CpG-oligodeoxynucleotides in Chronic Inflammation and Remodeling of Airway in a Murine Model of Bronchial Asthma

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.6, pp.543-552







& (2004). Effects of CpG-oligodeoxynucleotides in Chronic Inflammation and Remodeling of Airway in a Murine Model of Bronchial Asthma. Tuberculosis & Respiratory Diseases, 57(6), 543-552.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : Airway remodeling of the asthmatic airway, the result of persistent inflammation in the bronchial wall, is associated with irreversible airway obstruction and the severity of asthma. Previous reports had represented that adminitering CpG-oligodeoxynucleotides (CpG-ODN) before sensitization or challenge by allergens inhibits the development of eosinophilic airway inflammation in a murine model of asthma, but the effects of CpG-ODNs on chronic inflammation and airway remodeling had not been characterized. To investigate the influence of CpG-ODNs on chronic inflammation and remodeling of the airway, we performed studies using a murine model of chronic allergen-induced asthma. Methods : Balb/C mice were sensitized to ovalbumin(OVA) and subsequently exposed to nebulized OVA by means of inhalation twice weekly for 7 weeks. CpG-ODNs(30 μg) was administered intraperitoneally at sensitization. After final inhalation, mice were evaluated for airway hyperresponsiveness, chronic airway inflammation and remodeling. Results : The mice exposed to chronic and recurrent airway challenge with OVA had persistent airway hyperresponsiveness, chronic inflammation and airway remodeling. Mice treated with CpG-ODNs exhibited decreased bronchial hyperresponsiveness, OVA-specific IgE, chronic inflammation and evidence of airway remodeling, including goblet cell hyperplasia and subepithelial fibrosis. Conclusion : CpG-ODNs was thought to prevent chronic inflammation and remodeling changes in a murine model of chronic asthma. (Tuberc Respir Dis 2004; 57:543-552)

keywords
CpG-oligodeoxynucleotides, airway remodeling, murine model of asthma, CpG-oligodeoxynucleotides, airway remodeling, murine model of asthma

Reference

1.

(1989) Subepithelial fibrosis in the bronchi of asthmatics,

2.

(1992) Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack,

3.

(1997) Airway wall remodeling in asthma,

4.

(1993) The lack of distensibility of asthmatic airways,

5.

(1997) Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine,

6.

(1992) Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma.A quantita- tive light and electron microscopic study,

7.

(1998) Dexamethasone activates expression of the PDGF-alpha receptor and induces lung fibro- blast proliferation,

8.

(2001) Atopic disorders: a vaccine around the corner? ,

9.

(1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1)immunity,

10.

(1998) Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma,

11.

(2001) The effect of allergen-induced airway inflammation on airway remodelling in a murine model of allergic asthma,

12.

(1998) An improved murine methacholine responsiveness following chronic exposure to aerosolised allergen,

13.

(2002) Amb a 1-linked CpG oligodeoxy- nucleotides reverse established airway hyperres- ponsiveness in a murine model of asthma,

14.

(2000) CpG oligodeoxynucelotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma,

15.

(1999) Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides,

16.

(1999) Oligonulceotide therapy of allergic asthma,

17.

(1999) CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma,

18.

(1998) Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma,

19.

(1999) How BCG led to the discovery of immunostimulatory DNA,

20.

(1998) Type I interferon-mediated stimulation of T cells by CpG DNA,

21.

(1999) Oligodexoynucleotides containing CpG motifs induce IL-12,IL-18 and INF-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro,

22.

(1998) Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice,

23.

(1998) Bacterial DNA and immuno- stimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells,

24.

(1999) CpG DNA:a potent signal for growth,activation,and maturation of human dendritic cells,

25.

(1988) In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and-gamma with deoxyribonucleic acid fraction from Mycoba- cterium bovis BCG,

26.

(1995) CpG motifs in bacterial DNA trigger direct B-cell activation,

27.

(1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1)immunity,

28.

(2001) CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice,

29.

(1997) Bacterial DNA causes septic shock,

30.

(1999) Immunostimulatory CpG-oligode- oxynucleotides cause extramedullary murine hemo- poiesis,

31.

(1999) Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy